Obama Administration Launches $55 Million Precision Medicine Cohort Database Covering Over 1 Million Volunteers

Source: Translational Medicine Network

The Precision Medicine Initiative is an ambitious blueprint that requires physicians and healthcare professionals to tailor medications and treatments to individual patients based on their disease types, lifestyles, living environments, and genetic factors. This initiative outlines a revolution in the healthcare industry. However, before discussing precision medicine, we must first clarify what health truly means for an individual. This is precisely why the Obama administration announced this week an investment of $55 million in the fiscal year to establish a public database for precision medicine. According to the project plan, this database will encompass detailed health information from over one million volunteers to support disease research and the development of personalized drugs and therapies. Meanwhile, this new database will also help the U.S. government better regulate the rapidly growing genetic testing market.

This is the newly launched "Precision Medicine Cohort" database, a key component of the Precision Medicine Initiative (PMI), which NIH Director Francis Collins described in a press call as "the largest and most ambitious research project ever undertaken." The specific information covered by the Precision Medicine Cohort will include patients' medical records, genomic sequencing data, blood and urine test results, and even mobile health data collected from wearable devices and applications. Collins emphasized that the information in the Precision Medicine Cohort database will represent individuals of all races, ethnicities, and socioeconomic backgrounds. He also stated that the cohort will collect health data across different life stages and ages through long-term follow-up studies.

According to relevant information, the NIH’s $55 million investment will be specifically allocated to four sub-projects under the “Precision Medicine Cohort” initiative, including the establishment of a Data and R&D Support Center for the Precision Medicine Cohort, technical centers at collaborating institutions, and a network of Healthcare Provider Organizations (HPOs), among others. These efforts aim to promote data sharing and technology translation among research and industrial institutions participating in the Precision Medicine Initiative. Reported participants in the “Precision Medicine Cohort” project include renowned universities, research institutes, and industry organizations such as Vanderbilt University Medical Center, the Broad Institute, Verily Life Sciences (formerly Google Life Sciences), and the Scripps Research Institute.

As the Obama administration announced the launch of the Precision Medicine Initiative, the U.S. Food and Drug Administration (FDA) released a draft guidance document on oversight of genetic testing to ensure the safety of applying next-generation sequencing technologies in clinical practice. Currently, next-generation sequencing (NGS) technology enables rapid and cost-effective whole-genome sequencing, allowing for the swift identification of thousands of genetic abnormalities. However, the interpretation and clinical translation of genetic test results still face numerous challenges. Misinterpretation of these results may cause varying degrees of harm to patients, a concern that has drawn close attention from the FDA.

Currently, many genetic testing services can inform individuals whether they have a specific disease or are at risk for certain conditions, with some even directly recommending targeted therapies. The genetic testing market remains largely unregulated. The FDA seeks to leverage its market oversight capabilities to evaluate the accuracy and real-world clinical utility of these services, thereby regulating the rapidly expanding genetic testing market.

“Advanced testing technologies, such as genetic testing, are key to realizing the promise of the Precision Medicine Initiative,” said FDA Commissioner Robert Califf. However, the promise of precision medicine through genetic testing can only be fulfilled if “genetic testing correctly guides clinical diagnosis and treatment.” While Califf would not guarantee that new regulations will certainly be implemented, strengthening oversight of genetic testing companies is an inevitable choice for the FDA.